Home About us Reports Charts News Custom Company Scan  
Report Charts News
Title Content
Life Sciences
  Metals & Minerals
Public Sector
  Finance Service
  Real Estate
Technology And Media

Tel: 0086-10-82600828
Fax: 0086-10-82601570

 Merck Serono announced commercialization agreement with BeiGene Co of China
CreateTime:2013-11-14 Editor:liaoyan
Text Size:       

Merck Serono, the biopharmaceutical  division of Merck, today announced that a global licensing, co-development, and commercialization agreement for BeiGene-290 has been signed with BeiGene Co.,  Ltd., a biotech research and development company in Beijing, China. The compound,  which is a potent poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of  cancer, is currently in preclinical development and is expected to enter clinical  development next year. This is the second collaboration agreement between the two companies this year. 

Under the terms of the collaboration, BeiGene will be responsible for the development and commercialization of BeiGene-290 in China, and Merck will be responsible for the development and commercialization of BeiGene-290 for the rest of the world. BeiGene will receive an undisclosed upfront payment and is eligible to receive further payments of up to € 170 million (US$ 232 million) for the achievement of clinical development.

Related Reports
China Animal Vaccine Industry Report, 2019-2025
China Blood Product Industry Report, 2020-2026
China Vacuum Blood Collection Device Industry Report, 2019-2025
China Human Vaccine Industry Report, 2019-2025
China Independent Clinical Laboratory Industry Report, 2019-2025
2005-2021 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1